Schwab Andrew J.

Director Schwab buys 909,090 shares of CAMP at $11.00 ($10.0M); holdings rise 53.0% as part of 6-insider cluster buy pattern.

Director Andrew J. Schwab purchased 909,090 shares of Camp4 Therapeutics at $11.00 on 2024-10-15, increasing his post-transaction holdings to 2.63M shares—a 53.0% increase from his pre-transaction position of 1.72M shares. The transaction value of $9,999,990.00 reflects a substantial capital commitment from the insider. This purchase occurred as part of a cluster pattern in which 6 other insiders also bought within the past 14 days, suggesting coordinated or parallel confidence in the stock's value at current levels. The stock has since risen sharply—currently trading at $10.75—and the 52-week range of $0.40–$10.75 shows the stock is now at its 52-week high. This insider's cross-ticker track record shows 6 prior sells with an average 30-day return of -32.1%, though that historical metric does not directly bear on the timing of this particular buy decision or the company fundamentals driving the cluster pattern.

Director Andrew Schwab sold 266,337 shares (80.1% of holdings) for $1,750,352.22 across 6 transactions.

Andrew Schwab, a director at Skye Bioscience, executed 6 separate sales totaling 266,337 shares for $1,750,352.22 on September 11 and 13, 2024, reducing his holdings from 332,614 shares to 66,277 shares—an 80.1% reduction. The transactions occurred at blended average price of $6.57, while the company has a current price of $6.00 and is trading 66.7% below its 52-week high of $18.00. Notably, the company reported net income of $-7,902,816.00 for its most recent full fiscal year, indicating sustained unprofitability. The scale and proportion of this divestiture—liquidating four-fifths of a director's stake—warrants attention, particularly given the company's negative earnings profile and stock performance decline from the 52-week high.